Skip to content

Author

Satoshi Watanabe

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

A Retrospective Study of the Efficacy and Safety of Chemoimmunotherapy in Elderly Patients with Extensive-Stage Small Cell Lung Cancer

Simple Summary This retrospective study evaluated the effectiveness and safety of adding a programmed death-ligand 1 (PD-L1) inhibitor to platinum-based chemotherapy in patients aged ≥75 year with extensive-stage small cell lung cancer. The combination treatment significantly prolonged overall survival compared with ch...

Minoru Kobayashi, Satoshi Watanabe, S. Hirose et al. · 0 citations
Open access Sep 2026

Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.

INTRODUCTION First-line osimertinib monotherapy remains a standard treatment for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), although intensified regimens improve outcomes at the cost of an increased toxicity and treatment burden. We characterized pretreatment clinical f...

Masaki Ishida, T. Yamada, O. Yamaguchi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.